1 The presence of A(2) receptors mediating relaxation in the rat isolated aorta has been previously demonstrated. However, agonist dependency of the degree of rightward shift elicited by 8-sulphophenyltheophylline (8-SPT) led to the suggestion that the population of receptors in this tissue is not a homogeneous one. In this study we have re-examined the effects of 8-SPT in the absence and presence of the NO synthase inhibitor L-NAME (N-G-nitro-L-arginine methyl ester) and investigated antagonism of responses by the potent A(2a) receptor ligands PD 115,199 (N-[2-dimethylamino)ethyl]-N-methyl-4-(2, 3, 6, 7-tetrahydro-2, 6-dioxo-1,3 dipropyl-1H-purin-8-yl)) benzene sulphonamidexanthine), ZM 241385 (4-(2-[7-amino-2-(2-furyl) [1,2,4]-triazolo[2,3-a][1,3,5]triazin-5-yl amino]ethyl)phenol), and CGS 21680 (2-[p-(2-carboxyethyl)phenylamino]-5'-N-. We have also investigated the antagonist effects of BWA1433 (1,3-dipropyl-8-(4-acrylate)phenylxanthine which has been shown to have affinity at rat A(3) receptors. 2 Adenosine, R-PIA (N-6-R-phenylisopropyl adenosine), CPA (N-6-cyclopentyladenosine) and NECA (5'-N-ethylcarboxamidoadenosine) all elicited relaxant responses in the phenylephrine pre-contracted rat isolated aorta with the following potency order (p[A(50)] values in parentheses): NECA (7.07+/-0.11)>R-PIA (5.65+/-0.10)>CPA (5.05+/-0.12)>adenosine (4.44+/-0.12). 3 8-SPT (10 - 100 mu M) caused parallel rightward shifts of the E/[A] curves to NECA (pK(B) = 5.23+/-0.16). A smaller rightward shift of E/[A] curves to CPA was observed (pA(2) = 4.85+/-0.17). However, no significant shifts of E/[A] curves to either adenosine or R-PIA were observed. 4 In the absence of endothelium E/[A] curves to NECA and CPA were right-shifted compared to controls. However, removal of the endothelium did not produce a substantial shift of adenosine E/[A] curves, and E/[A] curves to R-PIA were unaffected by removal of the endothelium. 5 In the presence of L-NAME (100 mu M) E/[A] curves to NECA and CPA were right-shifted. However, no further shift of the CPA E/[A] curve was obtained when 8-SPT (50 mu M) was administered concomitantly. The locations of curves to R-PIA and adenosine were unaffected by L-NAME (100 mu M). 6 In the presence of PD 115,199 (0.1 CIM) a parallel rightward shift of NECA E/[A] curves was observed (pA(2) = 7.50+/-0.19). PD 115,199 (0.1 and 1 mu M) gave smaller rightward shifts of E/[A] curves to R-PIA and CPA, but E/[A] curves to adenosine were not significantly shifted in the presence of PD 115,199 (0.1 or 1 mu M). 7 The presence of ZM 241385 (3 nM - 0.3 mu M) caused parallel rightward shifts of NECA E/[A] curves (pK(B) = 8.73+/-0.11). No significant shifts of E/[A] curves to adenosine, CPA or R-PIA were observed in the presence of 0.1 mu M ZM 241385. 8 CGS 21680 (1 mu M) elicited a relaxant response equivalent to approximately 40% of the NECA maximum response. In the presence of this concentration of CGS 21680, E/[A] curves to NECA were right-shifted in excess of 2-log units, whereas E/[A] curves to R-PIA were not significantly shifted. 9 BWA1433 (100 mu M) caused a small but significant right-shift of the E/[A] curve to R-PIA yielding a pA(2) estimate of 4.1. IB-MECA (N-6-(3-iodo-benzyl)adenosine-5(1)-N-methyl uronamide) elicited relaxant responses which were resistant to blockade by 8-SPT (p[A](50) = 5.26+/-0.13). 10 The results suggest that whereas relaxations to NECA (10 nM - 1 mu M) are mediated via adenosine A(2a) receptors, which are located at least in part on the endothelium, R-PIA and CPA may activate A(2b) receptors on the endothelium and an additional, as yet undefined site, which is likely to be located on the smooth muscle and which is not susceptible to blockade by 8-SPT, PD 115,199 or ZM 241385. This site is unlikely to be an A(3) receptor since the very small shift obtained in the presence of BWA1433 (100 mu M), and the low potency of IB-MECA is not consistent with the affinities of these compounds at the rat cloned A(3) receptor. It is suggested that adenosine activates both the A(2a) and the undefined site, being most potent, but behaving as a partial agonist, at the A(2a) receptor.